SAG is a potent Smoothened (Smo) receptor agonist (Kd = 59 nM); antagonizes Cyclopamine action at the Smo receptor. SAG potently activates the Hedgehog signaling pathway in Shh-light 2 cells (EC50 ~ 3 nM). Induces pathway activation independently of Ptch proteins.
Description: Zosuquidar is an experimental antineoplastic drug currently under development. It has completed Phase 3 clinical trials in the United States. It inhibits P-glycoproteins. Other drugs with this mechanism include tariquidar and laniquidar.